Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Drug: EP-104GIOther: Matching vehicle control
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Eupraxia Pharmaceuticals Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT05608681
- Locations
- 🇦🇺
Campbelltown Private Hospital, Sydney, New South Wales, Australia
🇦🇺Eastern Health Box Hill, Box Hill, Victoria, Australia
🇦🇺Princess Alexandra Hospital, Brisbane, Queensland, Australia
Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee
- Conditions
- Osteoarthritis, Knee
- Interventions
- Drug: EP-104IAR 25 mgDrug: Vehicle
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Eupraxia Pharmaceuticals Inc.
- Target Recruit Count
- 318
- Registration Number
- NCT04120402
- Locations
- 🇨🇿
CCR Brno, s.r.o, Brno, Czechia
🇨🇿CCR Czech a.s, Pardubice, Czechia
🇨🇿CCR Prague, s.r.o, Prague, Czechia
Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Eupraxia Pharmaceuticals Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02609126
- Locations
- 🇨🇦
Rebalance MD, Victoria, British Columbia, Canada
🇨🇦Centre for Studies in Family Medicine, London, Ontario, Canada
🇨🇦Fowler Kennedy Sports Medicine Clinic, London, Ontario, Canada
News
Eupraxia's DiffuSphere Technology Shows Targeted Drug Release in Phase 2a EoE Program
Eupraxia Pharmaceuticals' DiffuSphere technology demonstrates targeted drug release in a Phase 2a trial for Eosinophilic Esophagitis (EoE).